A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

NCT00657449 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Acute Pain

Interventions

DRUG: valdecoxib
DRUG: rofecoxib

Sponsor

Pfizer